Scott Cameron: Metformin, Aspirin, and Sex-Specific Effects in Abdominal Aortic Aneurysm Growth
Scott Cameron, Vascular cardiologist at Cleveland Clinic, Section Head of Vascular Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Proud to share the third first‑author manuscript accepted from our National Heart, Lung, and Blood Institute funded Cleveland Clinic Lerner College of Medicine Prism Ph.D. student and former vascular medicine fellow, Fahad Alkhalfan.
Examining a large cohort of patients from the Cleveland Clinic Heart, Vascular, and Thoracic Institute, Dr. Alkhalfan shows that rapid abdominal aortic aneurysm (AAA) growth is mitigated by metformin and aspirin use.
Most strikingly, the data reveal a sex‑specific effect: ACE inhibitors and ARBs were associated with slower AAA growth ONLY in women.
Strict BP control is a Class I recommendation in the 2022 AHA/ACC guidelines for treating AAA medically, but there is less guidance on the class of medications to use
Another important piece of the AAA biology puzzle—and a clear reminder of why we must enroll more women in clinical trials and invest in mechanistic research focused on women’s cardiovascular health. Outstanding work and an important step toward more precise and equitable vascular care.”
Title: Sex-based differences in cardiovascular risk management and abdominal aortic aneurysm growth: Insights from a contemporary cohort study
Authors: Fahad Alkhalfan, Essa Hariri, Anu Aggarwal, Pulkit Chaudhury, Natalia Fendrikova Mahlay, Robert Burton, A. Phillip Owens III, Scott J. Cameron
Read Full Article on Atherosclerosis
Stay updated with Hemostasis Today.
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH
-
Sep 9, 2026, 16:07Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
-
Sep 9, 2026, 16:00Maximo Agustin Schiavone: HDL Beyond Cholesterol – Linking Lipids and Immunity
-
Sep 9, 2026, 15:56Abdul Mannan: When Antiseizure Drugs Alter DOAC Risk